Share

September 2021; 8 (5) Views & ReviewsOpen Access

Autoimmune Neurology

The Need for Comprehensive Care

Justin R. Abbatemarco, Stefanie J. Rodenbeck, Gregory S. Day, Maarten J. Titulaer, Anusha K. Yeshokumar, Stacey L. Clardy
First published June 15, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001033
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2142

Share

Article Information

vol. 8 no. 5 e1033
DOI: 
https://doi.org/10.1212/NXI.0000000000001033
PubMed: 
34131068
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 2, 2021
  • Accepted in final form May 3, 2021
  • First Published June 15, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Justin R. Abbatemarco, MD (justin.abbatemarco{at}hsc.utah.edu),
    2. Stefanie J. Rodenbeck, MD (stefanie.rodenbeck{at}hsc.utah.edu),
    3. Gregory S. Day, MD (day.gregory{at}mayo.edu),
    4. Maarten J. Titulaer, MD, PhD (m.titulaer{at}erasmusmc.nl),
    5. Anusha K. Yeshokumar, MD (anusha.yeshokumar{at}mssm.edu) and
    6. Stacey L. Clardy, MD, PhD
  1. Justin R. Abbatemarco, MD (justin.abbatemarco{at}hsc.utah.edu),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stefanie J. Rodenbeck, MD (stefanie.rodenbeck{at}hsc.utah.edu),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Gregory S. Day, MD (day.gregory{at}mayo.edu),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. DynaMed, EBSCO; ad-hoc Dementia Topic Editor for online evidence-based medicine resource; 2016-ongoing.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Parabon Nanolabs, Inc (advice / support for grant development and submission).

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Avid Pharmaceuticals (provision of radiotracer for completed research studies). 2. Eli Lilly, Roche, Biogen: Involved in clinical trials of anti-amyloid agents (no direct payments; research agreement between sponsor and institution).

    Research Support, Government Entities:

    1. 1. NIH/NIA: K23AG064029, PI, 2019-2024 2. NIH/NIA: U01AG057195, site-PI, 2021- 3. NIH/NIA: U19AG032438, site-PI, 2021-

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Chan Zuckerberg Foundation (Neurodegenerative Challenge Network), CS-0000000472, Clinical PI, 2019-2021 Stock/Stock Options, Medical Equipment & Materials: 1) Hold stocks (>$10,000) in ANI Pharmaceuticals (a generic pharmaceutical company; 2015 onward). 2) Parabon Nanolabs, Inc (stock options).

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. 1. Hendrick Medical Center, consultant concerning legal proceedings, 2018 2. Barrow Law, consultant concerning legal proceedings, 2018- 2021

  4. Maarten J. Titulaer, MD, PhD (m.titulaer{at}erasmusmc.nl),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology: Neuroimmunology & Neuroinflammation, since June 2014, (2) Dutch Journal for Neurology and Neurosurgery, since 2021.

    Patents:

    1. (1) filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Guidepoint Global LLC, research funds for consultancy; (2) Novartis, research funds for teaching; (3) CSL Behring, unrestricted research grant; (4) UCB, research funds for consultancy; (5) unrestricted research grant from Euroimmun AG.

    Research Support, Government Entities:

    1. (1) supported by the Netherlands Organisation for Scientific Research (NWO, Veni incentive and Memorabel initiative)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) supported by the Dutch Epilepsy Foundations, projectnumbers 14-19 and 19-08.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Anusha K. Yeshokumar, MD (anusha.yeshokumar{at}mssm.edu) and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Bristol Myers Squibb, Medical Director, 2021-present

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) American Epilepsy Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Stacey L. Clardy, MD, PhD
    7. Scientific Advisory Boards:

    1. Consulting/Ad Board: Alexion, VielaBio, Genentech, Guidepoint, ExpertConnect, Clarion Healthcare Consulting. (*Majority Fees to U.Utah Development account)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Section Editor, Neurology Podcast (July 2018-present) and Neurology Minute (March 2019-present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting/Ad Board: Alexion, VielaBio, Genentech, Guidepoint, ExpertConnect, Clarion Healthcare Consulting. (*Majority Fees to U.Utah Development account).

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research Support: Alexion, VielaBio. Site investigator: Alexion clinical trial for Eculizumab in Relapsing NMO patients (in extension).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research Support: The Siegel Rare Neuroimmune Association (SRNA), the Barbara Gural Steinmetz Foundation, the Sumaira Foundation for NMO.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (J.R.A., S.J.R., S.L.C.), University of Utah, Salt Lake City; Department of Neurology (G.S.D.), Mayo Clinic in Florida, Jacksonville; Department of Neurology (M.J.T.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Neurology (A.K.Y.), Icahn School of Medicine at Mount Sinai, New York; and George E. Wahlen Veterans Affairs Medical Center (S.L.C.), Salt Lake City, UT.
  1. Correspondence
    Dr. Clardy stacey.clardy{at}hsc.utah.edu
View Full Text

Article usage

Article usage: June 2021 to August 2023

AbstractFullPdfSource
Jun 2021143572429Highwire
Jul 202119956217Highwire
Aug 202118787139Highwire
Sep 202110680135Highwire
Oct 20214340106Highwire
Nov 2021313780Highwire
Dec 2021825885Highwire
Jan 2022530655Highwire
Feb 20221333560Highwire
Mar 2022833376Highwire
Apr 2022845574Highwire
May 2022939287Highwire
Jun 2022742444Highwire
Jul 2022437237Highwire
Aug 20221035246Highwire
Sep 2022837948Highwire
Oct 2022446145Highwire
Nov 20221034652Highwire
Dec 2022422931Highwire
Jan 20231038844Highwire
Feb 2023834235Highwire
Mar 2023633644Highwire
Apr 2023826633Highwire
May 2023733341Highwire
Jun 2023431723Highwire
Jul 2023730746Highwire
Aug 2023426030Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles